Skip to main content

Table 3 Summary of computed dosimetry

From: Towards personalised dosimetry in patients with liver malignancy treated with 90Y-SIRT using in vivo-driven radiobiological parameters

Cancer type

Dose (Gy)

BED \(\infty\) (Gy)

BEDexp (Gy)

TCP (%)

\(\Delta {\text{TLG}}_{{{\text{liver}}}}\)(%)

Breast

47.7

58.0

41.5

41.7

43.6

PNET

51.4

56.8

45.3

44.2

48.8

Adrenocortical carcinoma

52.7

67.7

26.2

17.6

23.7

CRC

127

170

90.1

65.6

75.5

Cholangiocarcinoma

28.1

46.2

46.1

50.6

56.9

CRC

33.3

37.6

6.03

0.12

− 113

CRC

42.6

53.0

43.3

42.8

47.7

Rectal adenocarcinoma

12.3

12.9

12.6

20.4

25.8

Cholangiocarcinoma

34.0

51.3

51.3

82.5

98.6

CRC

33.2

37.0

8.10

0.10

− 9.73

Cholangiocarcinoma

272

554

11.8

7.31

16.0

Cholangiocarcinoma

39.3

74.6

73.6

71.9

82.6

Sigmoid adenocarcinoma

53.0

62.7

61.9

54.6

70.3

Breast

45.6

93.0

93.0

79.1

89.0

Prostate

62.6

107

107

82.0

96.0

mCRC

29.5

34.2

32.7

32.1

37.5

PNET

42.2

60.9

60.7

50.8

57.0

PDAC

8.84

47.8

47.8

45.0

58.3

SBNET

231

368

368

81.3

85.1

Mesothelioma

59.9

62.5

69.9

60.6

65.7

PNET

97.8

116

116

72.8

80.3

HCC

80.6

134

12.5

0.27

0.15

Oesophageal

37.7

63.6

63.5

51.7

62.0

SBNET

50.0

55.1

40.3

31.5

35.0

NEC

17.1

21.9

10.5

0.32

− 2.29

  1. \(\Delta {\text{TLG}}_{{{\text{liver}}}}\), the total liver lesion glycolysis.